The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Given the success of Research Topic <a href=" in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Statin users had a significantly lower 10-year cumulative incidence of hepatocellular carcinoma and hepatic decompensation.

This is called secondary liver cancer or liver metastases. Hepatocellular carcinoma is also called hepatoma or HCC. It's the most common type of primary liver cancer. Because of this, the information ...